Other substances

Full-length Spike protein

An experimental COVID-19 protein vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Full-length Spike protein refers to SARS-CoV-2 Spike protein (adjuvanted) experimentally used as an immunogen (Kim et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice Spike protein Protein factor Animal model	BALB/c mice; (lentiviral) SARS-CoV-2 Spike-pseudotyped virus	4.09	The full-length version displayed higher immunogenicity compared to S1 or S2 domains only in mice. To induce sufficient immune response in aged mice, high-dose or adjuvanted (experimentally with AS01-like liposome adjuvant) version of the formulation was used.	Mar/29/2021

AI-suggested references

Link	Publication date
SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.	Sep/20/2021
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.	Mar/10/2022
Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque	Aug/01/2020
Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner	Dec/08/2021
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine	Dec/30/2020
Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection	May/12/2021
A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2	Nov/10/2021
Elucidating Interactions Between SARS-CoV-2 Trimeric Spike Protein and ACE2 Using Homology Modeling and Molecular Dynamics Simulations	Apr/08/2021
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency	Oct/26/2021
Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.	May/10/2021
BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.	Jun/18/2021
Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection	Apr/29/2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	Jun/08/2021
Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBDN318-V510) Expressed in Escherichia coli	Feb/15/2022
Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells	Dec/21/2020
SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET.	Jul/02/2021
Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination	Jun/12/2021
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model	Jan/21/2022
ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination	Mar/31/2022
A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2	Apr/22/2021
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?	Apr/19/2022
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein	Apr/04/2022
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate	Oct/20/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04998240	Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines in Mozambique	Not yet recruiting	Phase 2	Sep/01/2021	Oct/30/2022
Alternative id - IVI-ECOVA-02 Interventions - Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)\|Biological: AZD1222 (replication-deficient Ad type 5 vector expressing full-length spike protein) Study type - Interventional Study results - No Results Available Locations - Centro de Investigação e Treino em Saúde da Polana Caniço - Instituto Nacional de Saúde, Maputo, Mozambique Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 360 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Geometric Mean Titers (GMTs) of anti-SARS-CoV-2 neutralizing antibodies\|Incidence of SAEs and AESI observed at any time point during the entire study period\|Incidence of solicited reactions within 7 days (local reactions) and 14 days (systemic reactions)\|Incidence of unsolicited adverse events that are within 28 days after each vaccination\|Incidence of changes in laboratory safety measures from baseline to day 28 after each vaccination\|Geometric Mean Titers (GMTs) and Geometric Mean Fold Rise (GMFR)

Export (.csv)